NMTC NeuroOne Medical Technologies Corp

$NMTC Our Evo electrodes and OneRF brain ablation system will be showcased alongside Zimmer Biomet and Monteris technologies at the 2026 CNS Annual Meeting, October 31–November 4 in Washington, D.C., at Booth #649. Commercialized through our distribution partnership with Zimmer Biomet, these technologies support electrical recording and targeted radiofrequency ablation. OneRF enables diagnostic recording and ablation using the same sEEG electrode, connecting information gathering with treatment. Together with ROSA Brain’s robotic planning and guidance and NeuroBlate’s laser ablation, our products contribute to a portfolio spanning navigation, localization and ablation. CNS provides an opportunity for neurosurgeons to explore these complementary capabilities and see the practical role of NeuroOne’s technology within the broader workflow.

$NMTC Our StereoCED™ platform combines targeted intracranial drug delivery with electrophysiological recording, enabling researchers to monitor the brain’s electrical activity before, during and after drug administration. Designed to support electrode implantation for less than 30 days, StereoCED enables longitudinal EEG monitoring. This capability could help researchers examine changes in electrical activity and gain additional insights into a therapeutic agent’s effects over time. These integrated capabilities will support the preclinical program behind our first pharmaceutical industry purchase order, with research in large animals expected to begin in early 2027. For NeuroOne, this application extends our electrode technology into pharmaceutical research and supports our work to establish StereoCED within the drug development process.

$NMTC Today, we published preliminary product revenue results for fiscal Q4 and full-year 2026, reflecting continued commercial growth and a strong finish to the fiscal year. Q4 product revenue is expected to reach approximately $3.8 million, up 38.4% year over year. Full-year product revenue is expected to reach approximately $10.5 million, representing 15.6% growth and landing at the top of our previously announced guidance range of $9.2 million to $10.5 million. Reaching the upper end of that range marks an important execution milestone as we continue working to expand the commercial reach of our neurotechnology portfolio. The fourth-quarter performance also provides a stronger revenue foundation as we begin fiscal 2027. Figures are preliminary and unaudited, and remain subject to year-end accounting and audit procedures. Complete financial results are expected in December 2026.

$NMTC do they get paid too much? Probably. Imagine taking a job where you're not guaranteed success, you're not guaranteed FDA approval, you might have to start over....at the age of what 60? Rosa is no spring chicken. I am close to his age too...lil younger, I wouldn't risk my career on the unknown. Anyway, yeah, the SP sucks. Still here. No f's given.

$NMTC So why is a company with advanced, commercialized medical tech trading at these depressed levels? It comes down to structural Wall Street mechanics, not the underlying science. * The Wall Street Ban: Institutional funds are legally blocked from buying stocks under $5.00 or micro-caps under $100M. They literally cannot buy this yet. * Low Volume Trap: Low daily trading volume means big funds can't enter or exit positions without completely distorting the stock price. * Short-Term Noise: High-frequency algorithms and short-sellers exploit the low liquidity, while the market obsessively focuses on short-term cash burn rather than the multi-billion dollar long-term pipeline. The Bottom Line: The tech is validated, FDA-approved, and commercializing. For investors acting like venture capitalists, $NMTC offers asymmetric upside if you can look past the daily algorithmic noise.

$NMTC i can not even imagine watching my 10 yr old child have 50 seizures in 3 days.... our tech needs to reach more people soon.

$NMTC Another Press release, DOWN another 14%, keep those PR's coming. Reading some of these posts is just sad as big losing owners will cling to any excuse and any unrealistic dream in a desperate attempt to reinforce their own hype hope. They try to convice themselves so hard, they are just unable to see the forest for the trees, they just can not see the reality of their falsehoods.

$NMTC “When a technology alters the standard of care so profoundly that the old way of doing things becomes unthinkable, the eventual acquisition isn't valued by current sales metrics. It is priced as a multi-billion-dollar tollbooth on the future of neurology and spine care. The giants will pay an absolute king's ransom to own that tollbooth.”

$NMTC Since NeuroOne began publicly trading on August 4, 2017, at a split-adjusted price of $76.50, the stock has declined to $0.86 as of October 2026.This represents a total stock performance decline of 98.88% over the current CEO's tenure. He is paid $787K while the CFO gets $405K and the CTO $333K . For an 18 person company, given the cash burn and the historical stock performance, it really is egregious that top management gorges while shareholders bleed. I bought a small position late last year, which is now a tiny tiny position due to the decline this year. I blame myself , not management, because the info was publicly available and I should have passed given this, but it still boggles me that 1) there seems no pressure from the board or any institutional investors to replace top maangement, lower cash burn (inc salaries), and close deals w partners , and if all else fails, sell the company

$NMTC So, the algos decided to not take this into non compliance. How magnanimous of them. Get it cheap, but don't massacre them because they actually have a good device.

$NMTC delivers preliminary Q4 product revenue up 38.4% and announces a record $4.5 million purchase order.

$NMTC NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

$NMTC “The "Tuck-In" Acquisition Model: Large medical device companies rarely invent everything internally. Instead, they let micro-cap or small-cap innovators do the high-risk engineering and early clinical trials. Once the technology achieves FDA 510(k) clearances (which NeuroOne has done across multiple product lines), a major player can easily "tuck" that product into their global distribution network.”

$NMTC In the light, pride has no position and riches have no worth Things such as these are sentenced to the earth

$NMTC can’t hold gains. Company reaching with another average pr trying to prop up before announced dilution. Market is pricing this for at least 50% dilution with their ATM program. Hope it recovers to post split prices but seems very far away with today’s action. Would take a 400% move to get back to where it was 🙄

$NMTC $9.4m valuation! Nice job team. Crushing it. Must be pricing for massive dilution to keep ceos salary alive. Always thought this micro operated differently by not carrying debt and not a crazy cash burn rate. What a mistake that thought was. Just announce dilution already so investors can determine where the value should be.

$NMTC YES FOLKS, we have a BIG WINNER HERE, DOWN 80% from it's Reverse Split Price. Perhaps more HYPE posts from IR will help keep the hope alive.

$NMTC Buying more of this stock every day. While everyone cries about low prices, their muppet mouths will be shut when it rips.

$NMTC Under $10M market cap hahaha. What a dumpster fire. Not a word from them other than spam Stocktwits posts that provide nothing.

$NMTC $NMTC some funds do by policy refuse to trade microcaps. There is no law against it and there are plenty of investors and funds that buy microcaps. This company was down to two million in cash as of last report against about the same in quarterly losses. They are raising cash to survive via ATM and may need to do a larger discounted offering. Their sales are rising, but not fast enough to stop dilution. That is the reason stock is down, not some non-existent law about buying it...